Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab

Donald R Nixon, Nicholas AP Flinn Trimed Eye Center, Barrie, ON, Canada Purpose: This study evaluated visual function and anatomic and vision-related quality-of-life outcomes in recalcitrant neovascular age-related macular degeneration (AMD) subjects switched to aflibercept (Eylea®) from r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nixon DR, Flinn NAP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	contrast sensitivity neovascular age-related macular degeneration aflibercept ranibizumab NEI VFQ-25 Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/85bda4256c3f4696854c3401bdd21fa9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:85bda4256c3f4696854c3401bdd21fa9
record_format	dspace
spelling	oai:doaj.org-article:85bda4256c3f4696854c3401bdd21fa92021-12-02T04:10:16ZEvaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab1177-5483https://doaj.org/article/85bda4256c3f4696854c3401bdd21fa92017-04-01T00:00:00Zhttps://www.dovepress.com/evaluation-of-contrast-sensitivity-and-other-visual-function-outcomes--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Donald R Nixon, Nicholas AP Flinn Trimed Eye Center, Barrie, ON, Canada Purpose: This study evaluated visual function and anatomic and vision-related quality-of-life outcomes in recalcitrant neovascular age-related macular degeneration (AMD) subjects switched to aflibercept (Eylea®) from ranibizumab (Lucentis®). Methods: In a single-center study conducted in Barrie, ON, 40 patients with persistent fluid despite previous ranibizumab treatment were switched to aflibercept with 3 consecutive monthly doses. Main outcome measure was mean change from baseline to week 12 in Pelli–Robson contrast sensitivity (CS). Secondary outcomes were mean change in best corrected visual acuity (BCVA), central retinal thickness (CRT), and National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25) score. A two-sided paired t-test was used in the statistical data analysis to compare the means of continuous variables. Results: Forty-nine eyes (baseline visual acuity [VA] >6/120) were evaluated. Ranibizumab injections (mean ± standard deviation [SD] 28.2±22.1 [range 3–86]) were administered prior to treatment switch. Mean CS improved from 1.32 at baseline to 1.40 log units at week 12. VA was stable throughout. Mean CRT decreased from 354 µm at baseline to 332 µm at week 12 (-22 µm, P=0.004). Twenty-six (65%) patients experienced an overall improvement in NEI VFQ-25 score. Interestingly, a correlation was observed between improvement in log CS and CRT change (P=0.000046). Conclusion: Contrast sensitivity improved statistically and significantly, and CRT decreased from baseline to week 12 after a switch to aflibercept from ranibizumab. Analysis of CS as an independent outcome end point in neovascular AMD treatment switch studies may provide a more complete understanding of visual response. Keywords: contrast sensitivity, neovascular age-related macular degeneration, aflibercept, ranibizumab, NEI VFQ-25Nixon DRFlinn NAPDove Medical Pressarticlecontrast sensitivityneovascular age-related macular degenerationafliberceptranibizumabNEI VFQ-25OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 715-721 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	contrast sensitivity neovascular age-related macular degeneration aflibercept ranibizumab NEI VFQ-25 Ophthalmology RE1-994
spellingShingle	contrast sensitivity neovascular age-related macular degeneration aflibercept ranibizumab NEI VFQ-25 Ophthalmology RE1-994 Nixon DR Flinn NAP Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
description	Donald R Nixon, Nicholas AP Flinn Trimed Eye Center, Barrie, ON, Canada Purpose: This study evaluated visual function and anatomic and vision-related quality-of-life outcomes in recalcitrant neovascular age-related macular degeneration (AMD) subjects switched to aflibercept (Eylea®) from ranibizumab (Lucentis®). Methods: In a single-center study conducted in Barrie, ON, 40 patients with persistent fluid despite previous ranibizumab treatment were switched to aflibercept with 3 consecutive monthly doses. Main outcome measure was mean change from baseline to week 12 in Pelli–Robson contrast sensitivity (CS). Secondary outcomes were mean change in best corrected visual acuity (BCVA), central retinal thickness (CRT), and National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25) score. A two-sided paired t-test was used in the statistical data analysis to compare the means of continuous variables. Results: Forty-nine eyes (baseline visual acuity [VA] >6/120) were evaluated. Ranibizumab injections (mean ± standard deviation [SD] 28.2±22.1 [range 3–86]) were administered prior to treatment switch. Mean CS improved from 1.32 at baseline to 1.40 log units at week 12. VA was stable throughout. Mean CRT decreased from 354 µm at baseline to 332 µm at week 12 (-22 µm, P=0.004). Twenty-six (65%) patients experienced an overall improvement in NEI VFQ-25 score. Interestingly, a correlation was observed between improvement in log CS and CRT change (P=0.000046). Conclusion: Contrast sensitivity improved statistically and significantly, and CRT decreased from baseline to week 12 after a switch to aflibercept from ranibizumab. Analysis of CS as an independent outcome end point in neovascular AMD treatment switch studies may provide a more complete understanding of visual response. Keywords: contrast sensitivity, neovascular age-related macular degeneration, aflibercept, ranibizumab, NEI VFQ-25
format	article
author	Nixon DR Flinn NAP
author_facet	Nixon DR Flinn NAP
author_sort	Nixon DR
title	Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
title_short	Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
title_full	Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
title_fullStr	Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
title_full_unstemmed	Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
title_sort	evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/85bda4256c3f4696854c3401bdd21fa9
work_keys_str_mv	AT nixondr evaluationofcontrastsensitivityandothervisualfunctionoutcomesinneovascularagerelatedmaculardegenerationpatientsaftertreatmentswitchtoafliberceptfromranibizumab AT flinnnap evaluationofcontrastsensitivityandothervisualfunctionoutcomesinneovascularagerelatedmaculardegenerationpatientsaftertreatmentswitchtoafliberceptfromranibizumab
_version_	1718401382524911616

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab

Ejemplares similares